Eliana Merle
Stock Analyst
(1.86)
# 940
Out of 4,648 analysts
63
Total ratings
35%
Success rate
-8.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $74 | $47.07 | +57.21% | 2 | Nov 4, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $411 → $441 | $331.32 | +33.10% | 3 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $104 → $106 | $66.01 | +60.58% | 1 | Oct 30, 2024 | |
| ANAB AnaptysBio | Maintains: Neutral | $23 → $33 | $19.94 | +65.50% | 4 | Oct 30, 2024 | |
| MRNA Moderna | Maintains: Buy | $140 → $108 | $53.54 | +101.72% | 4 | Oct 24, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $97 → $131 | $108.97 | +20.22% | 6 | Sep 18, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $10 → $2 | $2.27 | -11.89% | 2 | Sep 9, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $85 → $83 | $28.56 | +190.62% | 7 | Aug 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $253 → $288 | $269.95 | +6.69% | 1 | Jun 28, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Neutral | $28 → $5 | $3.73 | +34.05% | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $25.20 | +86.51% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.90 | +28.21% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $7.10 | +153.52% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $42 | $32.05 | +31.05% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $55.87 | -28.41% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $25 | $9.29 | +169.11% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $5.56 | +655.40% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $2.71 | +564.21% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.89 | +802.63% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $8.84 | +148.87% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.76 | +436.53% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $11.33 | +41.22% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $26.80 | +358.96% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $26.71 | +401.68% | 3 | Aug 19, 2020 |
Kymera Therapeutics
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $47.07
Upside: +57.21%
Madrigal Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $331.32
Upside: +33.10%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Buy
Price Target: $104 → $106
Current: $66.01
Upside: +60.58%
AnaptysBio
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $19.94
Upside: +65.50%
Moderna
Oct 24, 2024
Maintains: Buy
Price Target: $140 → $108
Current: $53.54
Upside: +101.72%
BioNTech SE
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $108.97
Upside: +20.22%
RAPT Therapeutics
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $2.27
Upside: -11.89%
Apellis Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $28.56
Upside: +190.62%
Alnylam Pharmaceuticals
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $269.95
Upside: +6.69%
Zentalis Pharmaceuticals
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $3.73
Upside: +34.05%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $25.20
Upside: +86.51%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.90
Upside: +28.21%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $7.10
Upside: +153.52%
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $32.05
Upside: +31.05%
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $55.87
Upside: -28.41%
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $9.29
Upside: +169.11%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $5.56
Upside: +655.40%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.71
Upside: +564.21%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.89
Upside: +802.63%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $8.84
Upside: +148.87%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.76
Upside: +436.53%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $11.33
Upside: +41.22%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $26.80
Upside: +358.96%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $26.71
Upside: +401.68%